Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2015

Open Access 01-12-2015 | Research

Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy

Authors: Zhi-guo Zhou, Chan-jun Zhen, Wen-wen Bai, Ping Zhang, Xue-ying Qiao, Jun-li Liang, Xian-shu Gao, Shuo-shuo Wang

Published in: Radiation Oncology | Issue 1/2015

Login to get access

Abstract

Purpose

The aim of this study was to evaluate the salvage radiotherapy outcome in patients with local recurrent esophageal cancer after radical radiochemotherapy (RCT).

Methods

A total of 114 patients with local recurrent esophageal squamous cell carcinoma after initial radical RCT were retrospectively analyzed. Fifty-five (55) patients belonged to the salvage radiotherapy group (SR group) and 59 patients to the non-salvage radiotherapy group (NSR group).

Results

The median survival time after-recurrence was 4 months in all patients. The 1, 2, 3 year overall survival (OS) rates were 83.6%, 41.8% and 21.8% respectively in the SR group, and 57.6%, 16.9%, and 8.5% in the NSR group. The 6-month and 1-year survival rates after-recurrence were 41.8% and 16.4% respectively in the SR group, and 11.9% and 3.4% respectively in the NSR group. A salvage radiation dose > 50 Gy after initial radical RCT, improved the survival of patients with local recurrent esophageal cancer. Three patients (5.45%) from the SR group showed more than 3-grade radiation pneumonitis. In addition, esophageal fistula/perforation was observed in 11 cases (20.0%) in the SR group and in 8 cases (13.6%) in the NSR group.

Conclusions

Salvage treatment after definitive RCT may improve the overall survival and survival after-recurrence of patients with local recurrent esophageal cancer.
Literature
1.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.CrossRefPubMed
2.
Fujita H, Kakegawa T, Yamana H, Shima I, Tanaka H, Ikeda S, et al. Lymph node metastasis and recurrence in patients with a carcinoma of the thoracic esophagus who underwent three-field dissection. World J Surg. 1994;18:266–72.CrossRefPubMed
3.
Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus. 2006;19:73–7.CrossRefPubMed
4.
Shioyama Y, Nakamura K, Ohga S, Nomoto S, Sasaki T, Yamaguchi T, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007;37(12):918–23.CrossRefPubMed
5.
Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.CrossRefPubMed
6.
Sato N, Ishida K, Ikeda K, Koeda K, Ohtsuka K, Kimura Y, et al. Treatment of patients with recurrent esophagealcarcinoma. Gan To Kagaku Ryoho. 1998;25:314–20.PubMed
7.
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.CrossRefPubMed
8.
Harvey JA, Bessell JR, Beller E, Thomas J, Gotley DC, Burmeister BH, et al. Chemoradiation therapy iseffective for the palliative treatment of malignant dysphagia. Dis Esophagus. 2004;17(3):260–5.CrossRefPubMed
9.
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.CrossRefPubMed
10.
Berger B, Belka C, Weinmann M, Bamberg M, Budach W, Hehr T. Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma. Strahlenther Onkol. 2010;186:255–61.CrossRefPubMed
11.
Zwicker F, Roeder F, Thieke C, Timke C, Münter MW, Huber PE, et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol. 2011;187:32–8.CrossRefPubMed
12.
Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012;188(2):136–42.CrossRefPubMed
13.
Saeki H, Kawaguchi H, Araki K, Ohno S, Sugimachi K. Treatment strategy for and clinical results in patients with recurrent esophageal cancer. Nippon Geka Gakkai Zasshi. 1999;100(2):185–90. Japanese.PubMed
14.
Sugahara S, Ohara K, Okumura T, Irie T, Nakajima K, Itai Y. Patterns of initial treatment failure of esophageal cancer following radiotherapy. Nippon Igaku Houshasen Gakkai Zasshi. 1999;59:754–9. Japanese.
15.
Araújo CM, Souhami L, Gil RA, Carvalho R, Garcia JA, Froimtchuk MJ, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of thethoracic esophagus. Cancer. 1991;67:2258–61.CrossRefPubMed
16.
Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer. 2010;29(10):843–54.CrossRefPubMed
17.
Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123(1):175–83.CrossRefPubMed
18.
Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med. 1993;329(18):1302–7.CrossRefPubMed
19.
Raijman I, Siddique I, Ajani J, Lynch P. Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointest Endosc. 1998;48(2):172–9.CrossRefPubMed
20.
Zhang J, Peng F, Li N, Liu Y, Xu Y, Zhou L, et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol. 2012;7(1):93–100.CrossRefPubMedCentralPubMed
21.
Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(1):123–9.CrossRefPubMed
22.
Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Ohtomo K. Salvage radiotherapy for postoperative loco-regional recurrence ofesophageal cancer. Dis Esophagus. 2005;18:215–20.CrossRefPubMed
23.
Baxi SH, Burmeister B, Harvey JA, Smithers M, Thomas J. Salvage definitivechemo-radiotherapy for locally recurrent oesophageal carcinoma afterprimary surgery: retrospective review. J Med Imag Radiat Oncol. 2009;52:583–7.CrossRef
24.
Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment responseand prognosis of patients after recurrence of esophagealcancer. Surgery. 2003;133:24–31.CrossRefPubMed
25.
Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, et al. What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer? Curr Oncol. 2010;17(6):46–51.CrossRefPubMedCentralPubMed
26.
Jingu K, Nemoto K, Matsushita H, Takahashi C, Ogawa Y, Sugawara T, et al. Results of radiation therapy combined withnedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil forpostoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50. 1-9.CrossRefPubMedCentralPubMed
Metadata
Title
Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy
Authors
Zhi-guo Zhou
Chan-jun Zhen
Wen-wen Bai
Ping Zhang
Xue-ying Qiao
Jun-li Liang
Xian-shu Gao
Shuo-shuo Wang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2015
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-015-0358-z

Other articles of this Issue 1/2015

Radiation Oncology 1/2015 Go to the issue

Research

Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis

Methodology

The Focinator - a new open-source tool for high-throughput foci evaluation of DNA damage

Research

Stereotactic radiation therapy for liver metastases: factors affecting local control and survival

Research

Quality of life during 5 years after stereotactic radiotherapy in stage I non-small cell lung cancer

Short report

Perilesional edema in radiation necrosis reflects axonal degeneration

Research

Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer